PL3750913T3 - Epitop igg i jego zastosowanie jako cel - Google Patents

Epitop igg i jego zastosowanie jako cel

Info

Publication number
PL3750913T3
PL3750913T3 PL18904885.3T PL18904885T PL3750913T3 PL 3750913 T3 PL3750913 T3 PL 3750913T3 PL 18904885 T PL18904885 T PL 18904885T PL 3750913 T3 PL3750913 T3 PL 3750913T3
Authority
PL
Poland
Prior art keywords
target
application
igg epitope
epitope
igg
Prior art date
Application number
PL18904885.3T
Other languages
English (en)
Inventor
Xiaoyan Qiu
Jingshu TANG
Zhi Yang
Chong Wang
Jingxuan ZHANG
Hua Zhu
Zihan GENG
Yang Liu
Wenhua Jiang
Jing Huang
Original Assignee
Beijing SIG Biopharmaceutical Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing SIG Biopharmaceutical Technology Co., Ltd. filed Critical Beijing SIG Biopharmaceutical Technology Co., Ltd.
Publication of PL3750913T3 publication Critical patent/PL3750913T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL18904885.3T 2018-02-12 2018-08-08 Epitop igg i jego zastosowanie jako cel PL3750913T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810146884 2018-02-12
CN201810330585.1A CN108610414B (zh) 2018-02-12 2018-04-13 IgG抗原表位及其作为靶点的应用
PCT/CN2018/099279 WO2019153674A1 (zh) 2018-02-12 2018-08-08 IgG抗原表位及其作为靶点的应用

Publications (1)

Publication Number Publication Date
PL3750913T3 true PL3750913T3 (pl) 2024-03-04

Family

ID=63659963

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18904885.3T PL3750913T3 (pl) 2018-02-12 2018-08-08 Epitop igg i jego zastosowanie jako cel

Country Status (10)

Country Link
US (1) US20200369785A1 (pl)
EP (1) EP3750913B1 (pl)
JP (1) JP7156647B2 (pl)
CN (1) CN108610414B (pl)
ES (1) ES2965624T3 (pl)
HR (1) HRP20231636T1 (pl)
HU (1) HUE064723T2 (pl)
PL (1) PL3750913T3 (pl)
RS (1) RS64968B1 (pl)
WO (1) WO2019153674A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610414B (zh) * 2018-02-12 2022-09-13 北京大学 IgG抗原表位及其作为靶点的应用
CN109529051A (zh) * 2018-12-10 2019-03-29 大连医科大学 唾液酰基转移酶重组质粒及其与培美曲塞在制备抑制膀胱癌的增殖和侵袭药物中的应用
CN114409790B (zh) * 2022-03-31 2022-09-13 北京大学 一种提高抗体药物效力的方法及抗体药物
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102901817A (zh) * 2011-07-27 2013-01-30 北京大学 Non-B Ig单抗RP215在细胞增殖、迁移及干细胞研究中的应用
US8974786B2 (en) * 2012-06-13 2015-03-10 Vancouver Biotech Ltd. Humanized antibodies to CA215
CN105353132B (zh) * 2015-11-13 2018-04-10 北京大学 non B‑s IgG作为干/祖细胞标志物的应用
CN108610414B (zh) * 2018-02-12 2022-09-13 北京大学 IgG抗原表位及其作为靶点的应用

Also Published As

Publication number Publication date
EP3750913A1 (en) 2020-12-16
ES2965624T3 (es) 2024-04-16
RS64968B1 (sr) 2024-01-31
EP3750913C0 (en) 2023-09-13
JP2021528376A (ja) 2021-10-21
JP7156647B2 (ja) 2022-10-19
CN108610414B (zh) 2022-09-13
CN108610414A (zh) 2018-10-02
HUE064723T2 (hu) 2024-04-28
WO2019153674A1 (zh) 2019-08-15
US20200369785A1 (en) 2020-11-26
EP3750913A4 (en) 2021-08-25
EP3750913B1 (en) 2023-09-13
HRP20231636T1 (hr) 2024-04-26

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL279455A (en) ANTI-PD-1 antibodies and their uses
IL282968A (en) Anti-NKG2A antibodies and their use
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL280317A (en) Antibodies against AVB8 and preparations and their use
IL281297A (en) Anti-NPR1 antibodies and uses thereof
RS64968B1 (sr) Igg epitop i njegova primena kao cilja
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL276675A (en) Anti-PD-1 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL280281A (en) Anti-CD40 antibodies and uses thereof
IL283926A (en) Antibodies against alpha-synuclein and their uses
IL283180A (en) Anti-PD-1 antibodies and their uses
IL283890A (en) Anti-periostin antibodies and their uses
IL279790A (en) Anti-L1CAM antibodies and uses thereof
ZA202004784B (en) Humanized and de-immunized antibodies